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Themolecular determinants of spleen organogenesis
and the etiology of isolated congenital asplenia (ICA),
a life-threatening human condition, are unknown. We
previously reported that Pbx1 deficiency causes
organ growth defects including asplenia. Here, we
show that mice with splenic mesenchyme-specific
Pbx1 inactivation exhibit hyposplenia. Moreover,
the loss of Pbx causes downregulation of Nkx2-5
and derepression of p15Ink4b in spleen mesenchy-
mal progenitors, perturbing the cell cycle. Removal
of p15Ink4b in Pbx1 spleen-specificmutants partially
rescues spleen growth. Bywhole-exome sequencing
ofamultiplexkindredwith ICA,we identifyaheterozy-
gous missense mutation (P236H) in NKX2-5 showing
reduced transactivation in vitro. This study estab-
lishes that a Pbx/Nkx2-5/p15 regulatory module is
essential for spleen development.
INTRODUCTION
The vertebrate spleen is a secondary lymphoid organ and red
blood cell repository (Brendolan et al., 2007). It plays important
roles in host defense, via thematuration of B cells and the phago-
cytosis of circulating microbes by macrophages. Consistent
with this critical immunological function, congenital or acquired
asplenia is life threatening, due to invasive bacterial infections.DeveSpleen morphogenesis is achieved during development through
interactions between mesenchymal and invading endothelial
and hematopoietic cells. Genetically engineered mouse models
have led to the discovery of genes, mostly encoding transcrip-
tion factors, which are required for the temporal and spatial
coordination of cell-fate specification, cell proliferation, and
differentiation during spleen development. Transcription factor-
encoding genes Nkx2-3, Nkx3-2, Pbx1, Sox11, Wt1, and Tcf21
are expressed within the spleen primordium, and mice deficient
for these proteins exhibit spleen agenesis or hypoplasia, with
other organogenesis defects (Brendolan et al., 2005; Herzer
et al., 1999; Lettice et al., 1999; Lu et al., 2000; Pabst et al.,
1999; Sock et al., 2004). Additionally, the homeobox gene
Nkx2-5 marks progenitor cells of the spleen anlage, albeit its
role in spleen development has not been elucidated since
Nkx2-5 mutants die in utero before spleen specification (Lyons
et al., 1995). In contrast, Tlx1 (also known as Hox11) null mice
exhibit isolated asplenia without other abnormalities (Kanzler
and Dear, 2001; Roberts et al., 1994), mimicking human isolated
congenital asplenia (ICA, OMIM#271400; Mahlaoui et al., 2011).
Overall, only a few genes are known to control spleen develop-
ment in mice, by hitherto elusive mechanisms and interactions.
Human congenital asplenia can result from laterality defects,
i.e., failure to establish left-right (L-R) axis specification, as in
heterotaxy (Mahlaoui et al., 2011; Zhu et al., 2006), including
Ivemark syndrome with congenital anomalies of the heart or
great vessels (OMIM#208530). While >80 genes have been
implicated in L-R axis specification in model organisms, only
about 20 (including LEFTYA, CRYPTIC, and NKX2-5) have
been associated with human heterotaxy (Zhu et al., 2006).
Congenital asplenia can also be isolated and independent oflopmental Cell 22, 913–926, May 15, 2012 ª2012 Elsevier Inc. 913
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reveals hypoplastic spleens in some patients (Mahlaoui et al.,
2011). Since its first description, only 70 ICA patients (29
sporadic and 41 familial) have been reported in the literature,
mostly in childhood. We reported the only clinical series of ICA
patients (Mahlaoui et al., 2011). However, ICA is probably under-
diagnosed, as it often manifests with rapidly lethal infections that
prevent diagnosis unless necropsy is performed. Most known
children with ICA die of fulminant bacterial disease—invasive
pneumococcal infection in particular. Unlike heterotaxy, there
is no known genetic etiology for ICA, and mutations in TLX1,
which cause isolated asplenia in the mouse, have not been
reported in human ICA (Brendolan et al., 2007; unpublished
data). Our previous studies using a mouse strain with global
loss of Pbx1 (Pbx1/), which encodes a TALE homeodomain
transcription factor (Moens and Selleri, 2006), revealed general
organ hypoplasia and asplenia (Brendolan et al., 2005; Kim
et al., 2002). Accordingly, we set out to decipher the mecha-
nisms by which Pbx1 controls spleen morphogenesis and
growth by generating mice with conditional Pbx1 inactivation in
splenic mesenchymal progenitors. By this approach, we tested
the hypothesis that a Pbx-dependent spleen regulatory network
may be disrupted in ICA patients.
RESULTS
Spleen Hypoplasia Results from Pbx1 Inactivation
in Spleen Mesenchymal Progenitors
In the early mouse embryo, only mesenchyme and endothelium
form the spleen anlage, until hematopoietic cells invade at
embryonic day (E) 13.5 (Brendolan et al., 2007). Given the prime
role of Pbx1 in spleen organogenesis, we created a conditional
allele for spleen mesenchymal Pbx1 inactivation (Pbx1flox/flox;
see Figure S1 available online), to prevent in utero lethality and
non-cell-autonomous effects of Pbx1 loss in nonsplenic tissues.
Ubiquitous Cre-mediated Pbx1 inactivation with a b-actin Cre
strain (Lewandoski and Martin, 1997) recapitulated Pbx1/
phenotypes (Figures S2A–S2F).
We reasoned that crossing the Pbx1 conditional strain to a
line in which Cre expression is driven by endogenous Nkx2-5
cis-regulatory elements (Stanley et al., 2002) would yield
abnormal spleen growth, given findings that: (1) Nkx2-5 marks
splenic progenitors in Xenopus (Patterson et al., 2000) and
mouse (Burn et al., 2008; Hecksher-Sørensen et al., 2004); (2)
Pbx1 expression precedes Nkx2-5 in lateral plate mesoderm
(LPM; Figure S2G; Capellini et al., 2006), dorsal mesentery
(DM; Figure S2H), and splenopancreatic mesenchyme, including
the adjacent splanchnic mesodermal plate (Smp; Figure 1F;
Figure S2I), which give rise to the spleen anlage; (3) Pbx1 con-
trols Nkx2-5 expression (Brendolan et al., 2005); and (4) Pbx1
is required for cell proliferation in most embryonic organs,
including spleen (Brendolan et al., 2005).We inferred that splenic
Pbx1 inactivation would occur after onset of Nkx2-5 Cre expres-
sion, enabling Pbx1 to fulfill its role as a spleen specification
determinant in this strain. Thus, this model allows the study
of spleen morphogenesis and expansion, independent of
specification.
Using R26RLacZ mice (Figures 1A–1E; Soriano, 1999), we
revealed that Nkx2-5 Cre is first detectable at E9.5 on both914 Developmental Cell 22, 913–926, May 15, 2012 ª2012 Elsevier Insides of the visceral mesoderm (Figure 1B), where spleen
progenitors will arise. By E10.75, Cremarkedmore of the spleno-
pancreatic mesenchyme (Figure 1C), and was confined to the
splenic anlage to the left of the stomach by E11.5-12.5. The
prospective spleen capsule was devoid of Cre (Figures 1D and
1E). We also detected Nkx2-5 Cre in other domains, including
a minority of liver cells, as reported (Figures 1D and 1E; Stanley
et al., 2002). At E10.5, while Pbx1 was widespread in spleno-
pancreatic mesenchyme and Smp, Nkx2-5 was detected in
only a few mesenchymal cells (Figures 1F and 1G). By E11.5,
Pbx1 and Nkx2-5 Cre colocalized in most mesenchymal cells
of the anlage (Figures 1H–1J). Thus, the Nkx2-5 Cre line ap-
peared suitable for assessing Pbx1 roles in organ growth, after
splenic fate specification.
We demonstrated efficient Cre-mediated Pbx1 loss in spleen
mesenchyme of Pbx1DneoDex3/DneoDex3; Nkx2-5Cre/+ mice (here-
after Pbx1/Nkx2-5 Cre; Figures 1K–1N and insets). Pbx1 loss
mirrored Nkx2-5 Cre activity at E11.5 and E12.5 (compare Fig-
ure 1L with Figure 1D) and only 3%–5% of mesenchymal cells
in Pbx1/Nkx2-5 Cre spleens retained Pbx1 (insets in Figures 1L
and 1N). The prospective spleen capsule, which does not
express Nkx2-5 (Brendolan et al., 2005), retained Pbx1 (Figures
1L and 1N), and cells associated with splenic small vessels,
which do not arise from Nkx2-5-positive mesenchyme, also
showed low Pbx1 levels, as in postnatal day 3 (P3) mutant
spleens (Figures S2P–S2S). Thus, Pbx1 loss was permanent
(Figure S2S). All mutant mice (with neo [Pbx1Dex3/Dex3;Nkx2-
5Cre/+] or without neo [Pbx1DneoDex3/DneoDex3;Nkx2-5Cre/+])
formed hypoplastic and fragmented spleens (Figures 1P and
1R) with full penetrance. Since Wt1 also marks spleen mesen-
chyme (Brendolan et al., 2005; Hecksher-Sørensen et al.,
2004), we inactivated Pbx1 using the Wt1 Cre line (Wilm
et al., 2005), which resulted in similarly hypoplastic spleens
(Figures S1D and S1E), confirming that Pbx1 controls splenic
growth.
Spleen Hypoplasia, Resulting from a Tlx1
(Hox11)-Independent Proliferation Defect,
Is Exacerbated by Pbx1/Pbx2 Compound Loss
Loss of even one allele of Pbx2, which colocalizes with its family
member Pbx1 in the majority of spleen mesenchymal progeni-
tors (Figure S2K), on a Pbx1/Nkx2-5 Cre background, exacer-
bated spleen hypoplasia and fragmentation (Figures S6A–S6F).
Thus, Pbx1/2 exhibit overlapping functions in spleen morpho-
genesis and growth, as in skeletal development (Capellini
et al., 2006). We uncovered a significant decrease of mitotic
mesenchymal cells in the anlagen of Pbx1/Nkx2-5 Cre embryos
versus controls at different gestational days (Figures S5A and
S5B; quantifications in Figure 5I), while apoptosis was unaf-
fected (Figures S2T and S2U). We previously reported reduced
mesenchymal proliferation in Pbx1/ spleens, as in deficiency
of Tlx1. While Tlx1 was undetectable in Pbx1/ splenic anlage
(Brendolan et al., 2005), we found normal Tlx1 expression in
E14.5 Pbx1Dex3/Dex3;Pbx2+/;Nkx2-5Cre/+ anlagen versus
controls (Figures S5C and S5D). Moreover, we observed that
Tlx1-positive spleen progenitors are similarly present in wild-
type (WT) and Pbx1 mutant embryos at early stages of spleen
development (E11.5; Figures S5E and S5F). Since Tlx1 is
a splenic fate marker (Kanzler and Dear, 2001), required for cellc.
Figure 1. Pbx1 Inactivation in Nkx2-5-Positive Mesenchyme Causes Spleen Hypoplasia
(A–E) Whole mount (A), transverse (A inset, red box corresponds to plane of section indicated by red line; B and C), and sagittal (D–E) sections of
Nkx2-5Cre/+;R26R-LacZ embryos from E9.5 to E12.5, stained by b galactosidase.
(F and G) IHC for Pbx1b (F) and Nkx2-5 (black arrowheads) (G) in E10.5 WT transverse sections.
(H–J) Immunofluorescence (IF) on E11.5 Nkx2-5Cre/+sagittal sections. Colocalization (orange, J inset) of Pbx1 (red), which is widespread in the spleen, and Cre
(green) in spleen mesenchyme (outlined by white dashes).
(K–N) Immunohistochemistry (IHC) with a-Pbx1b on E11.5 and 12.5 sagittal sections from control (K and M) and Pbx1 conditional mutant (L and N) embryos,
showing Cre-mediated Pbx1 loss in all but a few positive cells (black arrowheads; insets).
(O–R) P1 and P7 control (O and Q) and homozygous mutant spleens (P and R).
Ao, aorta; C, coelomic cavity; DP, dorsal pancreas; G, gut; Go, gonad; L, liver; Smp, splanchnic mesodermal plate; Sp, spleen; St, stomach; WT, wild-type. See
also Figures S1 and S2.
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Figure 2. Pbx1 Ablation in Spleen Mesen-
chyme Causes Downregulation of Nkx2-5,
Essential for Spleen Growth
(A and B) IHC (E14.5 sagittal sections) shows few
Nkx2-5-positive cells in Pbx1 conditional mutants
(B) versus widespread Nkx2-5 in controls (A).
(C) qRT-PCR reveals a significant reduction of
Nkx2-5 mRNA in Pbx1 mutant versus control
spleen mesenchyme.
(D–G) Reduced Nkx2-5 levels inNkx2-5+/ (E), and
Nkx2-5Cre/GFP (G) mice result in smaller spleens
versus controls (D and F: P0 and E17.5).
(H) Diagram of the murine Nkx2-5 locus.
Enhancers directing expression in heart (green
boxes) and spleen-stomach (red box) indicated
(Figure S3).
(I) Pbx proteins bind to the Nkx2-5 spleen-
stomach enhancer, as assessed by ChIP. Primers
located within the enhancer (H, red arrows),
but not nonspecific primers (lane 5), amplify a
specific band from a-Pbx immunoprecipitated
chromatin from SPCL2 cells (lane 1; Experimental
Procedures).
(J) A Luc reporter containing WT Nkx2-5 spleen-
stomach enhancer (pGL3 Nkx2-5 WT) is trans-
activated approximately 2-fold when transiently
transfected into HEK293T cells versus a control
Luc reporter (pGL3-empty). This transactivation is
abolished when three predicted Pbx binding sites
within the enhancer have been mutated (pGL3
Nkx2-5 Mut).
Data are mean ± SEM of three independent
experiments performed in triplicate. P, pancreas;
Sp, spleen; St, stomach. See also Figure S3.
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tion (LOF) mice exhibit only asplenia (Roberts et al., 1994), our
findings confirmed that splenic specification is unperturbed in
this model, and that the hyposplenia is not due to inadequate
specification of spleen progenitors. Instead, expansion of these
progenitors was perturbed. Despite splenic hypoplasia, coloni-
zation of E14.5 mutant anlagen by erythroid (Vannucchi et al.,
2000) and endothelial (Baldwin et al., 1994) progenitors ap-
peared grossly normal (Figures S2X and S2Y). Since erythroid
colonization commences only around E14.5 (Sasaki and Matsu-
mura, 1988), the proliferation defect of Pbx mutant spleen
anlagen (Figures S5A and S5B) precedes this process. These
data, together with reduced proliferation in Pbx-deficient
mesenchymal cultures (below), underscore that spleen hypo-
plasia in this model resulted from a Tlx1-independent defect
in mesenchymal proliferation, highlighting the primary, cell-
autonomous role of Pbx in promoting splenic progenitor
expansion.
Pbx Directly Maintains Nkx2-5 Splenic Mesenchymal
Expression, which Is Essential for Spleen Growth
Like Tlx1, Nkx2-5 is detected in E10.5 splenopancreatic mesen-
chyme and in spleen progenitors thereafter (Figures 1A–1E and916 Developmental Cell 22, 913–926, May 15, 2012 ª2012 Elsevier In1G; Brendolan et al., 2005; Hecksher-Sørensen et al., 2004). It
also has roles in heart progenitor proliferation (Prall et al.,
2007). Pbx1 is required for Nkx2-5 initiation, as Pbx1/ embry-
onic spleens lack Nkx2-5 (Brendolan et al., 2005). In contrast,
Nkx2-5 Cre-mediated Pbx1 inactivation at E10.5, after Nkx2-5
expression onset, enabled assessment of the continued require-
ment of Pbx1 for Nkx2-5 maintenance during splenic growth.
Nkx2-5 was detected in a minority of mutant spleen cells (Fig-
ure 2B), compared to controls in which more than 90% of spleen
mesenchymal cells exhibit Nkx2-5 protein (Figure 2A). Addition-
ally, Nkx2-5 mRNA was significantly reduced in mutant versus
control spleens (Figure 2C). Though Nkx2-5 is an early spleen
mesenchymal marker, its roles in spleen organogenesis are
unclear, due to early in utero lethality of null mutants (Lyons
et al., 1995). Different Nkx2-5 partial loss-of-function (LOF)
alleles (Experimental Procedures), including Nkx2-5+/ mice
(Lyons et al., 1995), Nkx2-5Cre/GFP hypomorphic embryos (Prall
et al., 2007), and Nkx2-5Y-A:IRESLacZ/+ wild-type chimeras, a
dominant-negative model of Nkx2-5 deficiency conferred by
mutation of a conserved tyrosine-rich domain (Elliott et al.,
2006), showed hyposplenia (Figures 2D–2G and 6D). These
mouse models demonstrated that Nkx2-5 is critical for spleen
growth, as reduced Nkx2-5 dosage and mutations in differentc.
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precipitation (ChIP) on the Nkx2-5 spleen-stomach enhancer
(Figure 2H; Reecy et al., 1999), which contains two predicted
binding sites for Pbx-Hox and one for Pbx-Prep (Figure S3),
using SPCL2 cells with an a-Pbx antibody (Ab), showed marked
amplification of a region-specific PCR product, but not of an
outside control DNA fragment (Figure 2I). Luciferase (Luc)
reporter assays conducted by transfecting a pGL3 reporter (con-
taining the Nkx2-5 spleen enhancer upstream of Luc) into
HEK293T cells revealed a consistent 2-fold transactivation rela-
tive to empty pGL3 vector. Critically, this transactivation was
abolished when using a Nkx2-5 spleen enhancer reporter in
which the Pbx-Hox and Pbx-Prep binding sites were mutated
(Figure 2J). These findings established the requirement of
Nkx2-5 for spleen development and of Pbx1/2 for maintenance
of its expression in spleen progenitors in vivo, via binding to its
spleen enhancer.
Pbx1 Directly Represses the Cell-Cycle Inhibitor
p15Ink4b in Spleen Expansion
In RT-PCR arrays (Experimental Procedures), only the CDK
inhibitor p15 (known as Cdkn2b; Figure 3A) was significantly
perturbed in Pbx mutant spleens among cell cycle regulators
(Miller et al., 2007). It was upregulated more than 6-fold in
E13.5 and E14.5 mutant spleens (E13.5 in Figure 3B; Table
S1), but was not significantly upregulated in Pbx1/Nkx2-5 Cre
mutant hearts or pancreata (Figures S4D and S4E). Although
p15 often acts downstream of TGF-b signaling (Reynisdo´ttir
and Massague´, 1997), we did not observe dysregulation of other
TGF-b-associated genes in mutant spleens (Table S1).
The p15 cis-regulatory elements (Figure 3A; Staller et al.,
2001), conserved among vertebrates, bear three Pbx-Prep/
Meis binding sites (Figure S4A). Electrophoretic mobility shift
assays (EMSAs) on SP6 nuclear extracts with oligonucleotides
(oligos 1-3, Figure 3A) containing one of the binding sites, and
an a-Pbx1b Ab, identified a supershifted band (Figure 3C;
Figures S4B and S4C; Berthelsen et al., 1998), indicating binding
of a Pbx1b-Prep/Meis complex. ChIP assays on SPCL2 cells
using primers within the promoter region bearing Pbx-Prep/
Meis binding sites (Figure 3A, green arrows) showed amplifica-
tion of a specific band from a-Pbx-immunoprecipitated DNA
(Figures 3D, lane 1; Figure S4F), demonstrating Pbx binding to
the p15 promoter in the spleen anlage. Cotransfection of
increasing concentrations of Pbx1b expression vector with
a Luc reporter containing p15 regulatory sequences in NIH 3T3
cells (Figure 3E) revealed a dose-dependent repression of Luc
activity. In contrast, a Luc reporter controlled by a ubiquitous
promoter showed no decrease in activity when cotransfected
with Pbx1b. These findings demonstrated that Pbx binding
represses p15 transcription in the spleen anlage, in contrast to
human hepatocellular carcinoma cell lines, in which p15 was
cooperatively activated by Pbx1/Meis (Bjerke et al., 2011).
In WT spleen anlagen, p15 colocalized with the mesenchymal
marker vimentin (Figure 3F and insets), indicating that the prolif-
eration defect is intrinsic to mesenchyme, and not to colonizing
cells. p15 was not detected in Pbx1-positive cells in E16.5
(Figures 3G and 3H) WT and mutant spleen anlagen. Cells nega-
tive for both proteins were likely nonmesenchymal (hematopoi-
etic and endothelial) cells colonizing the spleen by E16.5. TheDevemutual exclusion of p15 and Pbx1 was consistent with direct
p15 repression by Pbx1 in the spleen anlage.
Loss of Pbx1/2 in Cultured Spleen Mesenchymal Cells
Reduces Proliferation and Increases p15 Levels
Spleen mesenchymal cultures (Experimental Procedures) in
which Pbx1, Tlx1, and Nkx2-5 colocalize, reproduce the embry-
onic splenic mesenchymal environment in a controlled system
in vitro (Figures S5G–S5L). Pbx1 loss (by infection with lentiviral
shRNA-Pbx1; Experimental Procedures) in SP6 cells signifi-
cantly reduced cell proliferation versus controls (shRNA-scram-
bled; Figure 4A). Asynchronous cells infected by shRNA-Pbx1
showed reduced BrdU incorporation and accumulated in G0/
G1 and G2/M as compared to controls (Figure 4B). Moreover,
loss of Pbx1/2 increased p15 mRNA and protein levels in SP6
cells (Figures 4C and 4D). Pbx1 loss in SpM cells infected with
adenovirus-Cre (Ad-Cre) also significantly reduced cell prolifera-
tion versus controls infected by Ad Null (Figure 4E). Restoration
of Pbx1b expression via Ad-Pbx1b infection in Pbx1/2 mutant
cells ameliorated the proliferation defect versus Pbx1/2 mutant
cells infected with Ad Null (Figure 4F). These results established
cell-autonomous requirements for Pbx1/2 in spleen mesen-
chymal cell proliferation in vivo and in vitro. We do not exclude
that hematopoietic or endothelial cells may also be affected by
Pbx loss in the splenic mesenchyme, but all the data described
above indicate that they are not primarily responsible for the
observed organ hypoplasia.
Genetic Ablation of p15Ink4b, which Is Bound
by Nkx2-5 in Its cis-Regulatory Elements, Partially
Rescues the Spleen Phenotypes
p15/mice are fertile (Latres et al., 2000), and we observed that
their spleens are indistinguishable fromWT during development.
E15.5-E17.5 spleens from Pbx1Dex3/Dex3;p15/;Nkx2-5Cre/+
embryos appeared morphologically larger and closer to WT
size, versus Pbx1Dex3/Dex3;p15+/+;Nkx2-5Cre/+ littermates (Fig-
ures 5A–5F and 6G–6I). Thus, splenic expansion was partially
rescued on a p15 null background. In each spleen, we quantified:
(1) size; (2) morphology (number of discrete anlagen); and (3)
mesenchymal proliferation. Surface area measurement was
chosen as opposed to volumetric analysis, due to the fragility
and fragmentation of the minute, thin mutant spleens (Experi-
mental Procedures). Defects in mutant spleen volume or weight,
as well as the degree of rescue, would likely bemore striking. We
observed a significant (p < 0.02) increase of about 30% in the
size of rescued spleens versus mutants (Figure 5G). Also,
rescued spleens, lacking p15, always formed one single,
compact anlage, as in controls, while Pbx1 mutants on
a p15+/+ background formed multiple, distinct splenules (Fig-
ure 5H; Figure S6F). We confirmed that Pbx1 inactivation in
spleen mesenchyme significantly reduced proliferation, while
loss of p15 function in Pbx1/Nkx2-5 Cre mutants significantly
(p < 0.05) increased proliferation to near WT levels (Figure 5I).
In sum, absence of p15 in Pbx1;Nkx2-5 Cre mutants resulted
in: (1) significant rescue of spleen size; (2) complete rescue of
spleen fragmentation; and (3) significant rescue of mesenchymal
proliferation. Together, these findings demonstrated that repres-
sion of p15 by Pbx is required for organ morphogenesis and
growth in vivo.lopmental Cell 22, 913–926, May 15, 2012 ª2012 Elsevier Inc. 917
Figure 3. Binding of Pbx1 to the p15Ink4b Promoter Is Associated with p15Ink4b Repression
(A) p15 locus on mouse chromosome 4. Region upstream of p15 (red box) with evolutionarily conserved sequences (blue peaks). Oligonucleotides for EMSA
assays: colored lines. Primers for ChIP: green arrows. Sequence of the p15 promoter (orange box) shown in Figure S4A.
(B) qRT-PCR of total RNA reveals significant upregulation of p15 in mutant embryonic spleens versus controls. GAPDH mRNA, internal control.
(C) EMSA with radiolabeled oligo-1 (blue line; A) containing a Pbx-Prep/Meis binding site (black box). Spleen mesenchymal cell nuclear extracts probed with
oligo-1, and treated with a-Pbx Ab (lane 4), resulted in a supershifted band (SS), indicating Pbx binding. Binding specificity confirmed by competition from excess
unlabeled WT (lanes 6 and 7), but not mutated oligo (lanes 8 and 9).
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Figure 4. Loss of Pbx1/2 in Cultured Spleen
Mesenchymal Cells Reduces Proliferation
and Increases p15Ink4b Levels
(A) SP6 cells after infection with a lentivirus con-
taining short hairpin RNAs specific for Pbx1
(shRNA Pbx1, gray line), exhibit significantly
reduced cell number over four passages, versus
cells infected with a control lentivirus carrying
a scrambled shRNA sequence (shRNA scrambled,
black line).
(B) Asynchronous SP6 cells infected with shRNA
Pbx1 show reduced BrdU incorporation versus
scrambled shRNA, and accumulate in G0/G1 and
G2/M. Loss of Pbx1 reduces percentage of cells in
S phase of the cell cycle (p = 0.003), and increases
percentage of cells in G0/G1 (p = 0.004) and G2/M
(p = 0.032).
(C) Asynchronous (I) and serum-released (II)
growing SP6 cells infected by shRNA Pbx1
exhibit increased p15 mRNA versus shRNA
scrambled.
(D) Western blot shows reduced Pbx1b and
increased p15 in shRNA Pbx1-infected SP6 cells
versus control. a-Vinculin, loading control.
(E) Pbx1 inactivation in SpM cells by infection with
a Cre-expressing adenovirus (Ad-Cre, gray line)
significantly reduces cell number over three
passages (P), versus SpM cells infected by control
adenovirus (Ad Null, black line). Data are mean ±
SEM of one representative experiment out of
a total of three performed in triplicate.
(F) Reintroduction of Pbx1b by an adenovirus
expressing Pbx1b (Ad-Pbx1b), performed four
days after Ad-Cre-mediated Pbx1 inactivation,
produces a significant increase in cell number (black line) after two passages (P), versus SpM cells infected by Ad Null (gray line).
Data are mean ± SEM of one representative experiment out of a total of two performed in triplicate. See also Figure S5.
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ure 5J; Figure S4F), which is also bound by Pbx, suggesting
control of p15 also by Nkx2-5. Supporting this hypothesis,
transfection experiments revealed that transient expression of
NKX2-5 in NIH 3T3 cells represses transcription of a Luc reporter
controlled by p15 regulatory elements, similarly to transfection
of Pbx1b (Figure 5K). RT-PCR analysis on p15/ spleens did
not show substantial perturbation of Nkx2-5 mRNA levels rela-
tive to WT (Figure 5L), indicating likely unidirectional control of
p15 by Nkx2-5, and highlighting the central role of Nkx2-5 within
this spleen regulatory module.
Heterozygous Missense NKX2-5 Mutation in a Human
Kindred with ICA
We set out to identify genetic etiologies of human ICA by whole-
exome sequencing (WES; Alcaı¨s et al., 2010; Bolze et al., 2010;
Byun et al., 2010). We investigated an African kindred (Family E;
Mahlaoui et al., 2011) with three ascertained cases (I.1, II.4, and(D) ChIP shows Pbx binding to the p15 promoter. Primers within the promoter (p15
a distinct band from a-Pbx immunoprecipitated chromatin (lane 1).
(E) Transient transfection of NIH 3T3 cells with Pbx1 causes a dose-dependent
independent experiments performed in triplicate.
(F) IF on E13.5 WT transverse sections. p15 (red) colocalizes in cells (white arrow
(G and H) IF on sections from E16.5 WT (G) and Pbx1Dex3/Dex3;Nkx2-5Cre/+ (H) sp
Pbx1b-positive cells (green).
See also Figure S4 and Table S1.
DeveII.5) of ICA (Figure 6A; case report in Experimental Procedures).
We hypothesized that ICA segregated as a fully penetrant,
autosomal dominant (AD), Mendelian trait in this family. The
number of reads and the exome coverage metrics (Table S2)
show inferior quality of the assembly for the exome of patient
II.4 compared to the two other patients (42% of target bases
covered at 103 compared to 72% and 71%), probably due to
suboptimal quality of II.4 genomic DNA (gDNA), which was
extracted from necropsy samples. Therefore, we selected candi-
date variations present in all three patients (I.1, II.4, and II.5), or
present in I.1 and II.5 and not covered by WES in II.4 (Table
S3). After filtering out known polymorphisms (Experimental
Procedures), we identified only 32 variants that could underlie
ICA in this family (Tables S3 and S4).
Of the 32 candidate variants identified, a substitution in
NKX2-5 was the only one affecting a gene known to be involved
in mouse spleen development (Table S4). This variant is
a missense heterozygous c.707C > A in protein-coding exon 2Ink4b IN1; A; green arrows), but not nonspecific primers (OUT2; lane 5) amplify
reduction in p15 promoter activity. Data are mean ± SEM of one out of four
s, insets) exhibiting high levels of the mesenchymal marker vimentin (green).
leens. Insets correspond to areas within red boxes. p15 (red) is not present in
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Figure 5. Genetic Ablation of p15Ink4b, which Is Bound by Nkx2-5 in Its cis-Regulatory Elements, Partially Rescues the Spleen Phenotypes
(A–F) Partial rescue of spleen size and morphogenesis in E15.5 (A–C) and E16.5 (D–F) Pbx1Dex3/Dex3;Nkx2-5Cre/+ mutants on a p15-deficient background.
Embryonic spleens (outlined in white) in whichPbx1 has been deleted in themesenchyme either alone (E and F) or withPbx2 (B and C), show a significant increase
in spleen size and rescued morphology on a p15-deficient background (medium white arrows; C and F), versus littermates which retain p15 (thin white arrows;
B and E). Control spleens (thick white arrows; A and D) for comparison.
(G–I) Summary of genetic rescue data at E16.5. (G) Spleen surface area measurements (Experimental Procedures) normalized to controls reveal that p15 null
Pbx1mutant spleens are significantly larger than p15+/+mutant spleens (p = 0.014). (H) All rescued embryos develop one single spleen anlage. (I) Proliferation rate
in p15/mutant spleen mesenchyme is restored to near WT levels, significantly higher than in p15+/+ Pbx1mutants (p = 0.038). Number of samples (n) indicated
on corresponding bar of each graph. P, pancreas; Sp, spleen; St, stomach.
(J) ChIP shows Nkx2-5 binding to the p15 promoter. Primers located within the p15 promoter (p15Ink4b IN2), but not nonspecific primers (OUT1, OUT2, and
OUT3), amplify a specific product from aNkx2-5-immunoprecipitated chromatin from SPCL2 cells, as assessed by qPCR and normalized to amplification of input
chromatin.
Developmental Cell
Genetics of Spleen Organogenesis
920 Developmental Cell 22, 913–926, May 15, 2012 ª2012 Elsevier Inc.
Developmental Cell
Genetics of Spleen Organogenesisof NKX2-5 (NM _004387.3, MIM600584) that changes proline at
amino acid position 236 to histidine, p.P236H (P236H hereafter;
Figures 6B and 6C). Sanger sequencing of peripheral blood
gDNA and cDNA from EBV-transformed B cells (EBV-B) of the
ICA patients confirmed that the P236H variant segregated with
ICA in all family members examined. All patients, but no healthy
relatives, were heterozygous for P236H (Figure 6A; Figure S7A).
The variant was not found in 1,052 additional healthy individuals
from the Centre d’Etude du Polymorphisme Humain and Human
Genome Diversity panels, nor in the 1,197 samples sequenced
by the 1,000 Genomes project, which together include 327
individuals of Sub-Saharan African origin (Table S5). These
results suggest that P236H is a rare, potentially ICA-causing
variant rather than an irrelevant polymorphism. Lastly, proline
at position 236 is evolutionarily conserved, although an alanine
is present at this position in Mus musculus (Figure 6C). No
species in which Nkx2-5 has been sequenced bears a histidine
at this position. We also examined copy number variants
(CNVs) throughout the II.5 genome (Supplemental Experimental
Procedures). We did not observe any CNV larger than 50 kb that
was not present in the DGV database (http://projects.tcag.ca/
variation/) or our own database of 150 samples. Overall, these
genetic data suggest that P236H is associated with ICA in this
multiplex kindred.
Biological Characterization of the Human NKX2-5
Mutant Allele
Because PolyPhen-2 (Adzhubei et al., 2010) predicted that the
P236H mutation is benign and residue 236 is outside the
NKX2-5 homeodomain, we hypothesized that the mutation
may not impair the production of the protein or its DNA binding.
Western blot and EMSA confirmed that NKX2-5 P236H is
produced and binds to DNA similarly to WT protein (Figure S7).
We hypothesized that the mutation may disrupt transactivation
by NKX2-5, probably through interaction with spleen-specific
cofactors. P236 lies immediately adjacent to the first of nine tyro-
sines that define a conserved tyrosine-rich domain (YRD; resi-
dues 237–275; Figure 6C), which our previous work established
as a critical domain for the in vivo function of Nkx2-5, as well as
its transcriptional activity in a heterologous context (Elliott et al.,
2006).Mouse chimeras composed partly of mutant cells in which
tyrosines in the Nkx2-5 YRD have been replaced by alanines (El-
liott et al., 2006) develop hypoplastic spleens (Figure 6D). Thus,
we posited that the P236H mutation could potentially impact
YRD function and the interaction of NKX2-5 with splenic
cofactors.
To test the effects of P236H on the transactivation potential
of Nkx2-5, we employed a heterologous system previously
used to study Nkx2-5 function in mouse heart development
(Elliott et al., 2006). The human NKX2-5 C-terminal domain, con-
taining either WT or mutant sequence, was fused to the Gal4
DNA-binding domain (DBD) and cotransfected into HEK293T(K) Transient transfection of NIH 3T3 cells with 800 ng of Pbx1b, NKX2-5 WT
(500 ng each), causes a reduction in p15 promoter activity. Transactivation norma
three independent experiments performed in triplicate.
(L) Semi-qRT-PCR on E16.5 mouse splenic RNA does not reveal perturbations o
negative control for Nkx2-5 expression.
All data are mean ± SEM. TBP, TATA-binding protein. See also Figure S6.
Devecells with a Luc reporter (pGL4.31) downstream of UAS
elements. While the WT construct increased Luc activity about
30-fold versus control, the construct bearing P236H induced
approximately 3-fold lower activity (Figure 6E). Mouse
constructs bearing mutations of critical YRD domain tyrosines
showed low Luc activity in this assay. Additionally, since Nkx2-5
is subject to autoregulation in heart development (Prall et al.,
2007), we transfected SPCL2 cells with the murine Nkx2-5
spleen enhancer Luc reporter (Figure S3) and expression vectors
for WT or P236H NKX2-5, with or without Tlx1, which is critical in
mouse spleen development (Kanzler and Dear, 2001; Roberts
et al., 1994). NKX2-5 WT cotransfected with Tlx1 activated
Nkx2-5 Luc approximately 2.5-fold above control, whereas this
transactivation was abolished when using NKX2-5 P236H
(Figure 6F). The same NKX2-5/Tlx1 cotransfection experiment
performed with HEK293T cells did not activate the Nkx2-5
Luc reporter, highlighting that this cooperative transactivation
of Nkx2-5 is spleen specific. These results demonstrated that
P236H impairs transactivation byNKX2-5, both in a heterologous
transactivation assay and in the context of spleen mesenchymal
progenitors. Given the findings in our mouse models, in which
reducedNkx2-5 gene dosage or YRD function yield hyposplenia,
and the observed in vitro functional deficiency of the NKX2-5
P236H rare allele identified in an ICA kindred, we conclude that
Nkx2-5 plays a central role in the development and growth of
the mammalian spleen.
DISCUSSION
Pbx1 is a prime regulator of the organogenesis of the spleen,
a vital but understudied organ. Here, we identified regulatory
pathways that control spleen growth in development. Pbx1/
mice exhibit numerous developmental defects (Capellini et al.,
2006; Ferretti et al., 2011; Kim et al., 2002; Selleri et al., 2001),
notably organ hypoplasia with diminished cell proliferation and
asplenia (Brendolan et al., 2005). Our mouse model with
spleen-specific Pbx1 loss afforded the dissection of Pbx roles
in spleen organogenesis distinct from those in specification.
Pbx1/Nkx2-5 Cre mice form spleen anlagen with defects in
morphogenesis and growth, and exhibit multiple, unjoined
splenules, indicating that Pbx loss affects the growth and
concomitantly the fusion of splenic progenitor condensations.
This strain therefore provides a model also for human polysple-
nia, a condition that occurs when independent mesodermal
condensations fail to fuse, as normally occurs in human develop-
ment, to form one cohesive spleen (Moore and Persaud, 2007;
Porembka et al., 2008). The growth defects observed in this
mouse model, in which Tlx1 expression is initiated and main-
tained, suggest that spleen fate determination occurs normally,
prior to Pbx1 inactivation, and that the proliferation defect is
Tlx1-independent. Pbx1 loss in Pbx1/Nkx2-5 Cre spleen anlage
downregulates Nkx2-5, for which we uncover roles in spleenor NKX2-5 P236H, or cotransfection of Pbx1b and NKX2-5 in combination
lized to empty expression vector (pcDNA3). Data are mean ± SEM of one out of
f Nkx2-5 in p15/ mutants versus controls. E16.5 WT pancreas RNA used as
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Figure 6. Characterization of an Inherited NKX2-5 Mutation in ICA Patients
(A) Pedigree of the family. Black symbols indicate confirmed ICA cases. Gray symbols indicate siblings who died early in childhood with clinical symptoms similar
to those of II.4. Haplotypes of NKX2-5 are indicated: M, c.707C > A; WT, wild-type allele; E?, unknown haplotype.
(B) Sequencing reads overlapping the mutation in exon 2 of NKX2-5 (g.172,659,827-g.172,659,852, hg19) displayed for patient I.1. Reads are reversed.
(C) The P236H mutation is plotted on a schematic diagram of the NKX2-5 protein (drawn to scale) showing conserved and/or functional domains (homeo-
domain: HD; tinman/Nkx2-5 domain: TN; NK2 specific domain: NK; tyrosine rich domain: YRD). Two other conserved domains, the NKX2-5 box and the
GIRAW motif, are indicated by yellow and green boxes, respectively. Evolutionary conservation of the NKX2-5 region containing amino acid P236 is repre-
sented below.
(D) Depicted are spleens fromNkx2-5Y-A:IRESlacZ/+4wild-type chimeric P0mouse pups (Prall et al., 2007). Chimeric spleens (right), with reduced Nkx2-5 function,
are smaller and dysmorphic, compared to WT (left).
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Figure 7. Pbx1 Is Present in the Early Spleen
Anlage, Where It Directs a Regulatory Module that
Converges on Nkx2-5, Controlling Organ Growth
and Morphogenesis
(A–C) Present at high levels in E13.5 spleen mesenchyme
(A), Pbx1 (green) ismarkedly reduced by P0 (B), and almost
completely absent from 6-week-old mouse spleens (C).
(D) During normal development, Pbx1/2 promote spleen
expansion via multiple pathways (black lettering and lines;
left): Pbx genes transactivate Nkx2-5 (and Tlx1, as re-
ported; Brendolan et al., 2005) in the spleen mesenchyme,
and repress the CDK-inhibitor p15. Moreover, like Pbx,
Nkx2-5 can also bind to the regulatory elements of p15 and
repress its transcription. Additionally, Nkx2-5 and Tlx1
likely act cooperatively (solid line) to transactivate target
genes in spleen mesenchyme. The pivotal role of Nkx2-5
within the Pbx-directed regulatory module is highlighted
by its central position within the depicted network.
Disruption in any component of this module (illustrated by
hollow fonts and dashed lines; right) can result in hypo-
splenia or asplenia in mice and humans. In particular,
complete asplenia results from global loss of Pbx1 or Tlx1
in the mouse (Brendolan et al., 2005; Roberts et al., 1994),
and is associated with mutation of NKX2-5 in ICA patients (scintigraphy image of patient II.4: white arrow indicates absence of uptake of 99 mTc-labeled
autologous red cells in the left abdomen below the liver, where the spleen should be located). Also, both spleen-specific Pbx1/2 inactivation and reduced Nkx2-5
dosage inmousemodels yield hyposplenia and perturbed spleenmorphogenesis. Green lettering and lines indicate findings described in this study; blue lettering
and lines indicate previously reported hierarchical genetic control (Brendolan et al., 2005; Roberts et al., 1994). B, bladder; d, dextrum (right side); KL, left kidney;
KR, right kidney; LL, left lobe of liver; LR, right lobe of liver; Sp, spleen; St, stomach.
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demonstrated here by hyposplenia in mouse models that have
either reduced Nkx2-5 dosage or mutations affecting Nkx2-5
function. Transactivation of Nkx2-5 is one likely mechanism
whereby Pbx1 governs spleen expansion (Figure 7D). Interest-
ingly, Nkx2-5 promotes cardiac progenitor cell proliferation (Prall
et al., 2007).
Pbx controls spleen growth also by transcriptional repression
of the CDK inhibitor p15Ink4b. p15/ mice develop normally,
though they acquire lymphoproliferative disorders as adults,
and compound loss of p15 with p18Ink4c results in spleno-
megaly (Latres et al., 2000). While it has been reported that
Pbx1 binds and transactivates p15 in human hepatic cancer
cell lines (Bjerke et al., 2011), our mouse models demonstrate
a repressive transcriptional control of p15 by Pbx in vivo in the
spleen anlage. This repression is validated by the partial rescue
of spleen growth andmorphogenesis when Pbx1 is ablated from
spleen mesenchyme in the absence of p15. Nkx2-5 also binds
the p15 promoter, linking the two Pbx-regulated pathways, and
partly accounting for spleen growth defects in models of Nkx2-
5 deficiency. Indeed, both Pbx1b and NKX2-5, either alone or
in combination, transcriptionally repress p15 in NIH 3T3 cells
(Figure 7). Interestingly, the NKX2-5 P236H mutant protein also(E) An expression vector encoding a construct consisting of the Gal4 DNA-bindin
a greater than 30-fold increase in transactivation when transiently cotransfected i
more than 50% when a fusion construct bearing the P236H mutation (NKX2-5 P
constructs in which all tyrosines in the YRD have been substituted with alanines o
2006), used as negative controls. Data are mean ± SEM of two independent exp
(F) HumanNKX2-5WT expression vector transiently cotransfected into SPCL2 ce
stomach enhancer (pGL3-Nkx2-5-Luc) increased transactivation nearly 3-fold rel
construct bearing the P236H mutation (NKX2-5 P236H) did not transactivate the
Data are mean ± SEM of four independent experiments performed in triplicate. S
Deverepresses p15 transcription. This finding suggests that this
particular mutation may perturb interaction of Nkx2-5 with
spleen-specific cofactors, and/or it may disrupt the regulation
of target genes other than p15 (such asNkx2-5 itself; see Figures
6E and 6F). Additionally, Nkx2-5 may control other cell-cycle
regulators, as suggested by the incomplete rescue of spleen
size by p15 loss, which further underscores the central role of
Nkx2-5 within this regulatory module.
To date, no existing mouse models with hyposplenia or asple-
nia have contributed to elucidating the genetic etiology of ICA,
a life-threatening asplenic condition without other abnormalities,
underreported and often undetected at birth (Mahlaoui et al.,
2011). Here, we delineate candidate genes and regulatory
modules that govern mammalian spleen organogenesis. Pbx
target genes identified in the mouse spleen anlage in this study
guided the analysis of WES data obtained from a human kindred
with ICA. This approach led to the identification of a missense
mutation in NKX2-5, which is a central component within the
Pbx-directed module in the mouse. This variant, not found as
a polymorphism in human populations, segregates with ICA in
all family members examined. P236H diminished transactivation
by Nkx2-5 in cultured spleen cells, which occurs only in
the presence of the splenic cofactor Tlx1, suggesting thatg domain fused to the C terminus of WT human NKX2-5 (NKX2-5 WT) causes
nto HEK293T cells with a UAS-Luc reporter. This transactivation is reduced by
236H) is used. Constructs expressing the Gal4-DBD alone, or mouse fusion
r phenylalanines (NKX2-5 Y- > A and NKX2-5 Y- > F, respectively; Elliott et al.,
eriments performed in triplicate.
lls with Tlx1 expression vector and a Luc reporter containing theNkx2-5 spleen-
ative to reporter alone. Cotransfection of Tlx1with mutated NKX2-5 expression
Luc reporter, nor did NKX2-5 WT, NKX2-5 P236H, or Tlx1 transfected singly.
ee also Figure S7 and Tables S2–S5.
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estingly, all known congenital heart disease (CHD) patients with
previously identified NKX2-5 mutations do not display asplenia
(Harvey et al., 2002), suggesting that these mutations, unlike
P236H, preferentially compromise heart development. Although
associated with ICA in vivo and deleterious in vitro, it is probable
but not certain that the P236H allele is the key factor underlying
ICA in this kindred. The generation of knock-in mutant mouse
lines or the identification of NKX2-5 mutations in other ICA
kindreds would provide further evidence. Meanwhile, this study
paves the way for analyses of ICA patients using WES and
other genome-wide approaches, and underscores the effective-
ness of evaluating human genetic research in conjunction with
analyses in mouse models.EXPERIMENTAL PROCEDURES
Mice
Pbx1 conditional mice were engineered by homologous recombination in E14
129/Ola ES cells (Figure S1; Hooper et al., 1987). Previously described mice
(Pbx1/, Pbx2/, Nkx2-5 Cre, Wt1 Cre, b-actin Cre, Nkx2-5+/, Nkx2-
5Y-A:IRESlacZ, Nkx2-5Cre/GFP, R26R-LacZ, and p15Ink4b) were used and geno-
typed as described (Biben et al., 2000; Capellini et al., 2006; Latres et al.,
2000; Lewandoski andMartin, 1997; Lyons et al., 1995; Prall et al., 2007; Selleri
et al., 2001; Soriano, 1999; Stanley et al., 2002; Wilm et al., 2005). Oligonucle-
otide primers for PCR genotyping in Supplemental Experimental Procedures.Assessment of b-Galactosidase Activity, Histology,
Immunohistochemistry, Immunofluorescence, Whole-Mount and
Section In Situ Hybridization, and TUNEL Assays
Protocols were as described previously (Brendolan et al., 2005; Selleri et al.,
2001). Antibodies are provided in Supplemental Experimental Procedures.
Single-stranded sense and antisense riboprobes specific for Tlx1 (Brendolan
et al., 2005) and Pbx1 (Capellini et al., 2006) were used for in situ hybridization.RT-Profiler Array Screening and Quantitative Reverse
Transcriptase-PCR
Total RNA and cDNA were generated from pools of eight to ten E13.5 and
E14.5 Pbx1Dex3/Dex3;Pbx2/;Nkx2-5Cre/+ and Pbx1flox/flox;Pbx2/ spleens
with commercial kits (QIAGEN; SuperArray Bioscience). Expression of 168
genes was assessed by RT-Profiler PCRArray (SuperArray Bioscience). Differ-
entially-expressed candidate genes were validated by quantitative reverse
transcriptase (qRT)-PCR using SYBR Green (SuperArray Bioscience). For
semi-qRT-PCR, cDNA prepared as above.Chromatin Immunoprecipitation
ChIP was performed as described (Brendolan et al., 2005; Capellini et al.,
2006). Abs and PCR primers listed in Supplemental Experimental Procedures.In Vitro Transcriptional Assays
Typically, 800 ng of reporter plasmid was transiently transfected into NIH 3T3
cells, Pbx1/ MEFs, SPCL2 cells, or HEK293T using Lipofectamine 2000
(Invitrogen), or FuGENE HD Transfection Reagent (Roche). Reporter plasmids
were: p15Luc 1040/+70 (Li et al., 1995); pGL3-Luc containing 1 kb of the
murine WT Nkx2-5 spleen-stomach enhancer (Figure S3) or the enhancer in
which the Pbx-Hox and Pbx-Prep binding sites were mutated; 200–1,000 ng
of expression constructs containing cDNA of human WT or P236H mutant
NKX2-5; or of a pcDNA3 construct containing the Pbx1b cDNA (Berthelsen
et al., 1998); and 50 ng of control plasmid (pCMV-b-gal or Renilla luciferase).
For GAL4-UAS assays, 800 ng of the luciferase reporter vector pGL4.31
(Promega) was cotransfected into HEK293T cells with a pCMV construct
expressing the Gal4 DNA-binding domain fused to the YRD of human
NKX2-5 (Elliott et al., 2006), either WT or bearing the P236H mutation.924 Developmental Cell 22, 913–926, May 15, 2012 ª2012 Elsevier InElectrophoretic Mobility Shift Assays
EMSA as described (Brendolan et al., 2005) using nuclear extracts from
embryonic spleen mesenchymal cells, HEK293T cells, or in vitro translated
proteins. Oligonucleotides and Abs in Supplemental Experimental
Procedures.
Derivation of Spleen Stromal Cell Lines
Cell suspensions from embryonic spleens were expanded for 10–15
passages, according to the NIH 3T3 protocol (Todaro and Green, 1963).
Two immortal lines (SP2 and SP6) were obtained from E16.5 Pbx1+/+;Pbx2/;
one line (SpM) from E17-18 Pbx1flox/flox;Pbx2/; and one line (SPCL2) from
E16.5 WT C57Bl/6 spleens. Immortalized lines were used for growth curves,
FACS analysis, or ChIP.
Analysis of Genetic Rescue
Fixed, unstained E15.5, E16.5, and E17.5 spleens, stomach, and pancreas
were positioned flat and photographed using QCapture software (QImaging)
and spleen surface areas were measured with ImageJ (http://rsbweb.nih.
gov/ij). Within each E16.5 litter, the sizes of Pbx1mutant and rescued (lacking
p15) spleens were normalized to the average WT spleen size within that litter.
Sections from E16.5 WT, Pbx1 mutant, and rescued spleens were immuno-
stained with a-pH3 Ab, and mitotic cells counted using the StereoInvestigator
software (MBF Bioscience). About 1,000 cells were counted in each of three
embryonic spleens for each genotype.
Human ICA Case Report
Both parents, I.1 and I.2 (Figure 6A), originate from Congo-Brazzaville, Africa,
and their first three children died between 8 and 12 months of age of fulminant
sepsis. The index case II.4, born after the parents emigrated to France, died of
sepsis caused by a Streptococcus a hemolyticus at 23 months. 99 mTechne-
tium-labeled red blood cell scintigraphy (Bearn et al., 1992) revealed asplenia
in II.4 and necropsy confirmed ICA with normal heart and viscera disposition.
The parents report that the course of disease in the four children was strikingly
similar. Although no medical work-up was performed for the first three chil-
dren, a diagnosis of ICA is likely. The parents and their fifth child (II.5) were
screened and ICA was diagnosed when II.5 was 2 months old and the father
35 years old. Child II.5, now 13 years old, is under antibiotic prophylaxis
and has received appropriate immunizations. He is overweight (BMI =
28.2 kg/m
2
) and has autism. Despite the lack of antibiotic prophylaxis or
vaccinations, the father never experienced significant infections. Indeed,
incomplete clinical penetrance of autosomal dominant ICA is rare but has
been reported (Lindor et al., 1995).
IRB Approval
This study was approved by the local institutional review board (IRB #JCA-
0689). Written informed consent for participation in the study was obtained
from all patients and family members studied.
Massively Parallel Sequencing
DNA (3 mg) extracted from EBV-B cells from patients I.1 and II.5 or from tissues
conserved from the necropsy of II.4 was sheared with a S2 Ultrasonicator (Co-
varis). An adaptor-ligated library was prepared with the Paired-End Genomic
DNA Sample kit (Illumina). The SureSelect Human All Exon kit 38Mb (Agilent
Technologies) was used for exome capture. Single-end sequencing was per-
formed on a Genome Analyzer IIx (Illumina), generating 72 base reads.
Sequence Alignment, Variant Calling, and Annotation
BWA aligner (Li and Durbin, 2009) was used to align the obtained sequences
to the human reference genome (hg 19 build). Downstream processing was
performed with the Genome Analysis Toolkit (GATK; McKenna et al., 2010),
SAMtools (Li and Durbin, 2009), and Picard Tools (http://picard.sourceforge.
net). Substitution calls were made with a GATK UnifiedGenotyper and indel
calls with a GATK IndelGenotyperV2. All calls with a read coverage 23 and
a Phred-scaled SNP quality of 20 were filtered out. No other GATK filters
were applied. Variants were annotated and analyzed with software developed
in-house (SQL database query-driven system; Liu et al., 2011). Polymorphisms
reported in the National Center for Biotechnology Information (NCBI)
dbSNP build 134 and 1,000 Genomes Project databases (http://www.c.
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Genetics of Spleen Organogenesis1000genomes.org), or identified in our own database of 400 exomes, were
filtered out.SUPPLEMENTAL INFORMATION
Supplemental Information includes seven figures, five tables, and Supple-
mental Experimental Procedures and can be found with this article online at
doi:10.1016/j.devcel.2012.02.009.
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